PhyNexus specializes in purification of biomolecules such as proteins, plasmids and antibodies, and has developmed columns and robotics to miniaturize and automate the process. The columns are compatible with all of the major robotic liquid handlers. Through the acquisition, Biotage will be able to provide its global customers an enabling automation platform based on Dual Flow Chromatography and patented tip technology for higher throughput purification of biomolecules at the lab-scale. Biotage predicts that this platform has the future potential to address a growing multi-billion USD market.
"The acquisition is complementary to our existing offering and enables us to better address the growing biomolecules market. We are very much looking forward to accelerate our efforts in this fast emerging area,” says Biotage CEO Torben Jörgensen.
Right: The PhyNexus AutoPlasmid MMG with patented Dual Flow Chromatography technology.
Opioids: Choosing the Best Solution for your Laboratory
Notice of Discontinuation of Biotage ZIP® and Biotage ZIP® Sphere
An Environmental Chemist Speaks Out
Drugs of Abuse Urine Testing White Paper Updated to Include a Further 50 Analytes
Application Video 894: Extraction of Aldosterone and Angiotensin from Plasma